Subtype
Ocular Melanoma
CI-CAN-00001295Explore in graph →
62 active trials1 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001295Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (36)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06280040 | Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma | unknown | — | 20 | Medical University of ViennaOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06284512 | Uveal Melanoma - Comparative Study | unknown | — | 50 | Medical University of ViennaOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03068624 | Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | unknown | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06073548 | Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study(SALOME Quali) | unknown | — | 250 | Institut CurieOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT05889481 | Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma(MicroGenUM) | unknown | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | unknown | Phase 2 | 52 | Suthee RapisuwonOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT05077280 | A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma | unknown | Phase 2 | 40 | California Pacific Medical Center Research InstituteOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05402059 | Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice(ISABELLA) | unknown | — | 1,570 | MelanomaPRO, RussiaOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05179174 | The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma | unknown | — | 102 | University of CataniaOTHER | 2 | Jan 5, 2022 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05047276 | Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma(PULSE-UM) | unknown | Phase 1 / Phase 2 | 16 | José María Piulats RodríguezOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT02913417 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | unknown | Phase 1 / Phase 2 | 26 | David Minor, MDOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT02909517 | The Role of Inflammation in Ocular Tumours | unknown | — | 30 | Unity Health TorontoOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT02379000 | TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy | unknown | Phase 4 | 50 | Charite University, Berlin, GermanyOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT01377025 | A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma(STREAM) | unknown | Phase 2 | 200 | Prof. Dr. med. Max. E. ScheulenOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00489944 | Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma | unknown | Phase 2 | 50 | San Diego Pacific Oncology & Hematology AssociatesOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00757614 | Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom | unknown | — | 14,000 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01217398 | Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye | unknown | Phase 2 | 35 | Institut CurieOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00811200 | Treatment Of Radiation Retinopathy Trial(TORR) | unknown | Phase 2 / Phase 3 | 220 | Leiden University Medical CenterOTHER | 0 | Jul 2, 2009 | clinicaltrials |
| NCT00872391 | Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma | unknown | N/A | 155 | Medical University of ViennaOTHER | 1 | Mar 31, 2009 | clinicaltrials |
| NCT00459849 | Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma | unknown | N/A | 175 | Barnes Retina InstituteOTHER | 1 | May 9, 2008 | clinicaltrials |
| NCT00540930 | Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy | unknown | Phase 4 | 400 | Shields, Shields and AssociatesOTHER | 1 | Oct 8, 2007 | clinicaltrials |
| NCT00168870 | Study of Metastatic Ocular Melanoma | unknown | Phase 2 | 48 | Charite University, Berlin, GermanyOTHER | 1 | Aug 31, 2007 | clinicaltrials |
| NCT00406900 | Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma | unknown | — | 560 | Ludwig-Maximilians - University of MunichOTHER | 1 | Dec 6, 2006 | clinicaltrials |
| NCT00111046 | Pain Relief - Tramadol Versus Ibuprofen | unknown | Phase 1 / Phase 2 | 40 | Royal Liverpool University HospitalOTHER_GOV | 1 | Nov 10, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Mar 6, 2024source: clinicaltrials